Evidence map›Paper›PMID 33778794›Full record

ArticleThe Lancet regional health. Western Pacific2021

The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand-a country pursuing COVID-19 elimination.

Jason K Gurney, Elinor Millar, Alex Dunn, Ruth Pirie, Michelle Mako, John Manderson, Claire Hardie, Chris G C A Jackson, Richard North, Myra Ruka and 2 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Drivers and recent trends of hospitalisation costs related to acute pulmonary embolism.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Maintaining early diagnosis of pancreatic adenocarcinoma in Japan: Local resilience against COVID-19.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Nanoceria: an innovative strategy for cancer treatment.Cellular and molecular life sciences : CMLS · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Jason K GurneyTe Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Elinor MillarTe Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Alex DunnTe Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Ruth PirieTe Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Michelle MakoTe Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
John MandersonTe Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Claire HardieMidcentral District Health Board, Ruahine Street, Palmerston North, New Zealand.
Chris G C A JacksonDepartment of Medicine, University of Otago, Great King St, Dunedin, New Zealand.
Richard NorthBay of Plenty District Health Board, Cameron Rd, Tauranga, New Zealand.
Myra RukaWaikato District Health Board, Pembroke Street, Hamilton, New Zealand.
Nina ScottWaikato District Health Board, Pembroke Street, Hamilton, New Zealand.
Diana SarfatiTe Aho o Te Kahu - Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Health Promotion Agency · NZWaikato District Health Board · NZPalmerston North Hospital · NZUniversity of Otago · NZUrology Bay of Plenty · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic has disrupted cancer services globally. New Zealand has pursued an elimination strategy to COVID-19, reducing (but not eliminating) this disruption. Early in the pandemic, our national Cancer Control Agency (

methodsData were sourced (2018-2020) from national collections, including cancer registrations, inpatient hospitalisations and outpatient events. Cancer registrations, diagnostic testing (gastrointestinal endoscopy), surgery (colorectal, lung and prostate surgeries), medical oncology access (first specialist appointments [FSAs] and intravenous chemotherapy attendances) and radiation oncology access (FSAs and megavoltage attendances) were extracted. Descriptive analyses of count data were performed, stratified by ethnicity (Indigenous Māori, Pacific Island, non-Māori/non-Pacific).

findingsCompared to 2018-2019, there was a 40% decline in cancer registrations during New Zealand's national shutdown in March-April 2020, increasing back to pre-shutdown levels over subsequent months. While there was a sharp decline in endoscopies, pre-shutdown volumes were achieved again by August. The impact on cancer surgery and medical oncology has been minimal, but there has been an 8% year-to-date decrease in radiation therapy attendances. With the exception of lung cancer, there is no evidence that existing inequities in service access between ethnic groups have been exacerbated by COVID-19.

interpretationThe impact of COVID-19 on cancer care in New Zealand has been largely mitigated. The New Zealand experience may provide other agencies or organisations with a sense of the impact of the COVID-19 pandemic on cancer services within a country that has actively pursued elimination of COVID-19.

fundingData were provided by New Zealand's Ministry of Health, and analyses completed by Te Aho o Te Kahu staff.

Indexed as

CancerCancer registrationCancer servicesCancer treatmentCoronavirusCOVIDCOVID-19

Identifiers

PMID33778794
PMCPMC7983868
OpenAlexW3136681105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.